scholarly journals The Association between ANXA2 mutations and Clinical Pathological Features in Patients with Breast Cancer

2021 ◽  
Author(s):  
Jiayou Liu ◽  
Shaoli Xie ◽  
Linglong Mo ◽  
Lulan Pu ◽  
Mingfei Xu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Molecular Subtype ◽  
Clinical Stage ◽  
Missense Mutations ◽  
Early Screening ◽  
Tissue Samples ◽  
Node Metastasis ◽  
Cancer Tissues

Abstract Background Genetic mutations have been reported in many tumors. In this study, we aimed to examine whether ANXA2 mutations occur in breast cancer and to investigate their association with clinicopathological characteristics in patients. Materials and Methods We collected breast cancer and adjacent normal tissue samples from 112 patients, extracted total RNA, and performed PCR-SSCP and bidirectional Sanger sequencing. ANXA2 mutations were identified by NCBI BLAST (blastn and blastx), and their correlation with clinical data were analyzed. Results ANXA2 mutations were detected in breast cancer tissues (missense mutations 38.39%) at a higher incidence than in adjacent normal tissues (missense mutations 8.04%) and mainly located in domain and repeats 1. Moreover, mutations in breast cancer tissues were associated with clinical stages, molecular subtype, ER, PR, and lymph-node metastasis of patients. Within a mean follow-up time of 52.5 months, the 5-year OS of patients with missense mutations was lower than those without. Among those mutations, c.(350AG > GA), c.(375G > A), c.(487T > A) and c.(693G > A) were associated with younger patients. c.(350AG > GA) was related to higher clinical stage and lymph-node metastasis. c.(375G > A) was linked to HER2(-) cases, while c.(693G > A) tended to be TNBC cases. Conclusion ANXA2 missense mutations mainly occurred on domain and repeats 1 in breast cancer, which may be associated with pathogenesis, clinical stage, molecular subtyping, lymph node metastasis and 5-year OS of breast cancer. These mutations may contribute to the early screening, diagnosis, and targeted treatment of breast cancer.

scholarly journals Breast Cancer Combined with Contralateral Neck Lymph Node Metastasis. Case Report

2021 ◽  
Author(s):  
Xiaoxiao Zhong ◽  
Fengjiao Ding ◽  
Liyuan Qian ◽  
Wei Wu ◽  
Yanguang Wen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Clinical Stage ◽  
Pathological Examination ◽  
Cervical Lymph Nodes ◽  
Neck Lymph Node ◽  
Node Metastasis ◽  
Neck Lymph Node Metastasis ◽  
The Right

Abstract Background: Contralateral neck lymph node metastasis is rare for primary breast cancer. Its clinical stage and treatment principles are lack of authoritative guidelines. A 30-year-old breast cancer patient with contralateral neck lymph node metastasis is presented. The clinical treatment is discussed combined with current research.Case presentation: A 30-year-old woman presented with a right breast mass for 5 months and left neck lymph node enlargement for 5 days. The mammography showed a 33mm*14.3mm mass in the inner quadrant of right breast. The ultrasound showed several hypoechoic nodules on the left side of the neck. Rapid intraoperative pathological examination diagnosed right breast malignant tumor and poorly differentiated carcinoma of the left cervical lymph nodes. Then the right mastectomy was performed immediately. The patient was scheduled to administer chemotherapy, molecular targeted therapy, radiotherapy and endocrinotherapy after operation. The long-term efficacy remains to be seen.Conclusion: The infrequent presentation of breast cancer with metastasis to the contralateral neck lymph node can be challenged for standard therapies.

Breast Cancer Molecular Subtype as a Predictor of Lymph Node Metastasis

2014 ◽  
Vol 90 (1) ◽  
pp. S267-S268
Author(s):  
J.K. Bhatia ◽  
D. Metzger ◽  
H. Ashamalla ◽  
E. Katsoulakis ◽  
M.D. Mattes
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Molecular Subtype ◽  
Node Metastasis

scholarly journals Neuropilin-1 expression is associated with lymph node metastasis in breast cancer tissues

2018 ◽  
Vol Volume 10 ◽  
pp. 1969-1974 ◽  
Author(s):  
Mahnaz Seifi-Alan ◽  
Roshanak Shams ◽  
Mojgan Bandehpour ◽  
Reza Mirfakhraie ◽  
Soudeh Ghafouri-Fard
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Node Metastasis ◽  
Neuropilin 1 ◽  
Cancer Tissues

Association of reduced XRCC2 expression with lymph node metastasis in breast cancer tissues

2014 ◽  
Vol 13 (4) ◽  
pp. 611-617 ◽  
Author(s):  
Nabiha Bashir ◽  
Syeda Sana ◽  
Ishrat Mahjabeen ◽  
Mahmood Akhtar Kayani
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Node Metastasis ◽  
Cancer Tissues

scholarly journals Correlation of breast cancer microcirculation construction with tumor stem cells (CSCs) and epithelial-mesenchymal transition (EMT) based on contrast-enhanced ultrasound (CEUS)

PLoS ONE ◽  
2021 ◽  
Vol 16 (12) ◽  
pp. e0261138
Author(s):  
Xiaoling Leng ◽  
Guofu Huang ◽  
Siyi Li ◽  
Miaomiao Yao ◽  
Jianbing Ding ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Histological Grade ◽  
Node Metastasis ◽  
Contrast Enhanced ◽  
Epithelial Phenotype ◽  
Cancer Tissues ◽  
Er Expression ◽  
E Cadherin

Objective This study is to explore the correlation between the contrast-enhanced ultrasound (CEUS) characteristics of breast cancer and the epithelial-mesenchyme transformation (EMT). Methods Totally 119 patients of breast cancer underwent CEUS. Tissues in the active area were collected and subjected to the immunohistochemical detection, PT-PCR and Western blot. Correlation analysis was conducted between the clinical pathological parameters and the CEUS indicators. Results The expression levels of CD44, N-cadherin, and β-catenin in breast cancer tissues were higher than those in adjacent tissues (P<0.05). However, the expression levels of CD24 and E-cadherin in breast cancer tissues were lower than those in adjacent tissues (P<0.05). There was no significant difference in E-cadherin mRNA and Vimentin levels between cancer and adjacent tissues (P>0.05). The expressions were up-regulated in the CSCs, with higher histological grade, lymph node metastasis, and negative estrogen receptor (ER) expression. Smaller breast tumors, with no lymph node metastasis, lower clinical stage, and positive ER expression, tended to exhibit the up-regulated epithelial phenotype. Breast tumors, with high histological grade, lymph node metastasis, high clinical staging grade, and negative ER expression, tended to exhibit the up-regulated interstitial phenotype. The peak intensity of the time-intensity curve (TIC) for the CEUS was positively correlated with the CSC marker CD44 and the interstitial phenotype marker N-cadherin. The starting time of enhancement was negatively correlated with the N-cadherin. Area under the curve was positively correlated with the expression of CD44 and N-cadherin, while negatively correlated with the epithelial phenotype marker β-catenin. The time to peak was negatively correlated with the interstitial phenotypes Vimentin and N-cadherin, with no correlation with the E-cadherin or β-catenin. Conclusion Breast cancers show the enlarged lesions after enlargement and perfusion defect for the CEUS. The fast-in pattern, high enhancement, and high perfusion in the TIC are correlated with the CSCs and EMT expressions, suggesting poor disease prognosis.

Sign in / Sign up

Export Citation Format

Share Document